To provide a quantitative method for predicting the individualized clinical prognosis on breast cancer patients, we next established a nomogram model that integrated the risk score and a series of clinical information including age, T/N stage, stage I/II/III/IV and molecular type (Basal, Normal, Her2, TNBC, Luminal A, Luminal B) in training cohort patients. This evidence concerns the gene ERBB2 and breast cancer.